With deep experience in corporate and business development, Dr. Azzi will work closely with adMare’s Venture Partners to build their portfolios through new program creation and advance adMare’s Mission to source therapeutically and commercially promising research from leading academic and biotech partners from across Canada to create and grow companies of scale.
With applications more than doubling for year two, the program Adjudication Committee has selected 19 executives, 10 women and 9 men, who have demonstrated impressive experience, accomplishment, and impact; and who span the Canadian industry from sea to sea (and even stretch south to the Bay Area, attracting a Canadian working at one of the world’s top biotech firms).
The NEOMED Innovation Centre will be expanded with the construction of a new innovation and commercialization complex specializing in life sciences and health technology Montreal, Quebec – adMare BioInnovations held…
With more than 25 years of experience in pharmaceutical R&D leadership and management, serving most recently as Site Head and VP of R&D at Vertex Pharmaceuticals Canada Inc., Dr. Bennani will be based in Montreal, and responsible for overseeing and advancing a portfolio of drug development and commercialization projects through management of a multi-disciplinary scientific and business team.
With its combined strength, adMare will prioritize high-value job creation through an impactful and sustainable Canadian life sciences industry; which will directly support the advancement of the Québec Life Sciences Strategy, Canada’s Innovation and Skills Plan, and the recommendations of the federal Health/Biosciences Economic Strategy Table.
NEOMED, CQDM, the Canadian Cancer Society, the Goodman Cancer Research Centre & the Lady Davis Institute announced a unique multi-party collaboration to develop new anti-cancer therapies.
Building off a highly successful inaugural year, CDRD, Canada’s life sciences venture, is proud to open applications to its 2019-2020 Executive Institute – a 10-month, highly-focused executive development program custom-designed to grow and nurture the management talent that the Canadian life sciences sector needs to lead the world.
By combining TRIUMF’s expertise in manufacturing isotopes and radiolabelling conjugates with CDRD’s ability to identify and validate potential biological targets to develop therapeutic agents such as monoclonal antibodies, new “weaponized targeted therapies” can be created for the treatment of cancers with significant unmet medical need. In doing so, the organizations are leveraging two of Canada’s complementary national strengths to create a unique global competitive advantage; while also enabling an integrated health sciences ecosystem that bridges the gap between academic research, commercialization, and patient care in targeted alpha therapeutics.
CDRD is a proud sponsor of the TAT11 International Symposium on targeted alpha therapy hosted by Canadian Nuclear Laboratories. We are excited to be co-hosting a panel discussion “The Renaissance…
NEOMED, GSK, CHUM Research Centre & University College London announced that they have entered into a strategic collaboration to explore the potential of a newly identified target for HIV immune therapy and cure.